This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Stocks Under $5 Outperforming in 2012

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

3. BioDelivery Sciences International (BDSI - Get Report)

Company Profile: BioDelivery Sciences is a specialty pharmaceutical company focused on pain management and oncology supportive care.

Shares of BioDelivery surged on Jan. 6 after the company struck a licensing and development deal with Endo Pharmaceuticals (ENDP). Endo said it will pay up to $180 million, plus royalties, to BioDelivery Sciences one of the company's pain treatments.

Share Price: $2.08 (Jan. 27)

2012 Total Return: 158%

Analyst Ratings: Following the announcement of the deal with Endo, Roth Capital, Ladenburg Thalmann and William Blair each came out reiterating "buy" ratings on the stock. The average of the three research firms' price target is $4.67, more than double where the stock currently trades. TheStreet Ratings has a "sell" rating on BioDelivery Sciences.

2. EntreMed (ENMD)

Company Profile: EntreMed is a pharmaceutical company that is looking to develop and commercialize drugs for the treatment of cancer and inflammatory diseases.

Shares of EntreMed rose last Monday after the company announced it secured $10 million in financing. Later in the week, EntreMed rallied sharply after stakeholder Celgene (CELG) announced it would acquire cancer drug maker Avila Therapeutics, which also develops kinase inhibitors.

Share Price: $2.60 (Jan. 27)

2012 Total Return: 173%

Analyst Ratings: No Wall Street firm currently has coverage of EntreMed. TheStreet Ratings has a "sell" rating on EntreMed.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

5 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CTC $0.68 0.00%
ENA $0.00 0.00%
CCGM $0.04 0.00%
BDSI $8.95 -3.30%
ENMD $1.18 1.72%


DOW 18,051.88 -28.26 -0.16%
S&P 500 2,114.39 -3.30 -0.16%
NASDAQ 5,073.7190 -18.3660 -0.36%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs